Altered mitochondrial function in cells carrying a premutation or unmethylated full mutation of the FMR1 gene

Springer Science and Business Media LLC - Tập 139 - Trang 227-245 - 2020
Veronica Nobile1, Federica Palumbo1, Stella Lanni2, Valentina Ghisio3, Alberto Vitali4,5, Massimo Castagnola5, Valeria Marzano5,6, Giuseppe Maulucci7, Claudio De Angelis7, Marco De Spirito7, Laura Pacini8,9, Laura D’Andrea8, Rino Ragno10, Giulia Stazi10, Sergio Valente10, Antonello Mai10, Pietro Chiurazzi1,3, Maurizio Genuardi1,3, Giovanni Neri1,11, Elisabetta Tabolacci1
1Istituto di Medicina Genomica, Università Cattolica del Sacro Cuore, Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, Italy
2Program of Genetics and Genome Biology, The Hospital for Sick Children, The Peter Gilgan Centre for Research and Learning, Toronto, Canada
3UOC Genetica Medica, Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, Italy
4Institute of Chemistry of Molecular Recognition, CNR, Roma, Italy
5Istituto di Biochimica e Chimica Clinica, Università Cattolica del Sacro Cuore, Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, Italy
6Human Microbiome Unit, Bambino Gesù Children’s Hospital IRCCS, Rome, Italy
7Istituto di Fisica, Università Cattolica del Sacro Cuore, Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, Italy
8Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy
9UniCamillus, Saint Camillus International University of Health and Medical Sciences, Rome, Italy
10Department of Chemistry and Technologies of Drugs, Sapienza University, Rome, Italy
11Self Research Institute, Greenwood Genetic Center, Greenwood, USA

Tóm tắt

Fragile X-related disorders are due to a dynamic mutation of the CGG repeat at the 5′ UTR of the FMR1 gene, coding for the RNA-binding protein FMRP. As the CGG sequence expands from premutation (PM, 56-200 CGGs) to full mutation (> 200 CGGs), FMRP synthesis decreases until it is practically abolished in fragile X syndrome (FXS) patients, mainly due to FMR1 methylation. Cells from rare individuals with no intellectual disability and carriers of an unmethylated full mutation (UFM) produce slightly elevated levels of FMR1-mRNA and relatively low levels of FMRP, like in PM carriers. With the aim of clarifying how UFM cells differ from CTRL and FXS cells, a comparative proteomic approach was undertaken, from which emerged an overexpression of SOD2 in UFM cells, also confirmed in PM but not in FXS. The SOD2-mRNA bound to FMRP in UFM more than in the other cell types. The high SOD2 levels in UFM and PM cells correlated with lower levels of superoxide and reactive oxygen species (ROS), and with morphological anomalies and depolarization of the mitochondrial membrane detected through confocal microscopy. The same effect was observed in CTRL and FXS after treatment with MC2791, causing SOD2 overexpression. These mitochondrial phenotypes reverted after knock-down with siRNA against SOD2-mRNA and FMR1-mRNA in UFM and PM. Overall, these data suggest that in PM and UFM carriers, which have high levels of FMR1 transcription and may develop FXTAS, SOD2 overexpression helps to maintain low levels of both superoxide and ROS with signs of mitochondrial degradation.

Tài liệu tham khảo

Alvarez-Mora MI, Rodriguez-Revenga L, Madrigal I, Guitart-Mampel M, Garrabou G, Milà M (2017) Impaired mitochondrial function and dynamics in the pathogenesis of FXTAS. Mol Neurobiol 54:6896–6902 Ariza J, Steward C, Rueckert F, Widdison M, Coffman R, Afjei A, Noctor SC, Hagerman R, Hagerman P, Martínez-Cerdeño V (2015) Dysregulated iron metabolism in the choroid plexus in fragile X-associated tremor/ataxia syndrome. Brain Res 1598:88–96 Ariza J, Rogers H, Hartvigsen A, Snell M, Dill M, Judd D, Hagerman P, Martínez-Cerdeño V (2017) Iron accumulation and dysregulation in the putamen in fragile X-associated tremor/ataxia syndrome. Mov Disord 32:585–591 Bagni C, Greenough WT (2005) From mRNP trafficking to spine dysmorphogenesis: the roots of fragile X syndrome. Nat Rev Neurosci 6:376–387 Borgstahl GE, Parge HE, Hickey MJ, Beyer WF Jr, Hallewell RA, Tainer JA (1992) The structure of human mitochondrial manganese superoxide dismutase reveals a novel tetrameric interface of two 4-helix bundles. Cell 71:107–118 Brykczynska U, Pecho-Vrieseling E, Thiemeyer A, Klein J, Fruh I, Doll T, Manneville C, Fuchs S, Iazeolla M, Beibel M et al (2016) CGG repeat-Induced FMR1 silencing depends on the expansion size in human iPSCs and neurons carrying unmethylated full mutations. Stem Cell Rep 7:1059–1071 Culotta VC, Yang M, O'Halloran TV (2006) Activation of superoxide dismutases: putting the metal to the pedal. Biochim Biophys Acta 1763:747–758 Darnell JC, Van Driesche SJ, Zhang C, Hung KY, Mele A, Fraser CE, Stone EF, Chen C, Fak JJ, Chi SW et al (2011) FMRP stalls ribosomal translocation on mRNAs linked to synaptic function and autism. Cell 146:247–261 Davidovic L, Navratil V, Bonaccorso CM, Catania MV, Bardoni B, Dumas ME (2011) A metabolomic and systems biology perspective on the brain of the fragile X syndrome mouse model. Genome Res 21:2190–2202 Fernández E, Rajan N, Bagni C (2013) The FMRP regulon: from targets to disease convergence. Front Neurosci 7:191 Ferrari F, Mercaldo V, Piccoli G, Sala C, Cannata S, Achsel T, Bagni C (2007) The fragile X mental retardation protein-RNP granules show an mGluR-dependent localization in the post-synaptic spines. Mol Cell Neurosci 34:343–354 Fivenson EM, Lautrup S, Sun N, Scheibye-Knudsen M, Stevnsner T, Nilsen H, Bohr VA, Fang EF (2017) Mitophagy in neurodegeneration and aging. Neurochem Int 109:202–209 Glineburg MR, Todd PK, Charlet-Berguerand N, Sellier C (2018) Repeat-associated non-AUG (RAN) translation and other molecular mechanisms in Fragile X tremor ataxia syndrome. Brain Res 1693:43–54 Hagerman PJ, Hagerman RJ (2004) The fragile-X premutation: a maturing perspective. Am J Hum Genet 74:805–816 Hukema RK, Buijsen RA, Raske C, Severijnen LA, Nieuwenhuizen-Bakker I, Minneboo M, Maas A, de Crom R, Kros JM, Hagerman PJ et al (2014) Induced expression of expanded CGG RNA causes mitochondrial dysfunction in vivo. Cell Cycle 13:2600–2608 Jacquemont S, Pacini L, Jønch AE, Cencelli G, Rozenberg I, He Y, D'Andrea L, Pedini G, Eldeeb M, Willemsen R et al (2018) Protein synthesis levels are increased in a subset of individuals with fragile X syndrome. Hum Mol Genet 27:3825 Kaplan ES, Cao Z, Hulsizer S, Tassone F, Berman RF, Hagerman PJ, Pessah IN (2012) Early mitochondrial abnormalities in hippocampal neurons cultured from Fmr1 pre-mutation mouse model. J Neurochem 123:613–621 Klemmer P, Meredith RM, Holmgren CD, Klychnikov OI, Stahl-Zeng J, Loos M, van der Schors RC, Wortel J, de Wit H, Spijker S et al (2011) Proteomics, ultrastructure, and physiology of hippocampal synapses in a fragile X syndrome mouse model reveal presynaptic phenotype. J Biol Chem 286:25495–25504 Lanni S, Goracci M, Borrelli L, Mancano G, Chiurazzi P, Moscato U, Ferrè F, Helmer-Citterich M, Tabolacci E, Neri G (2013) Role of CTCF protein in regulating FMR1 locus transcription. PLoS Genet 9:e1003601 Leboucher A, Pisani DF, Martinez-Gili L, Chilloux J, Bermudez-Martin P, Van Dijck A, Ganief T, Macek B, Becker JAJ, Le Merrer J, Kooy RF, Amri EZ, Khandjian EW, Dumas ME, Davidovic L (2019) The translational regulator FMRP controls lipid and glucose metabolism in mice and humans. Mol Metab 21:22–35 Lemasters JJ (2014) Variants of mitochondrial autophagy: types 1 and 2 mitophagy and micromitophagy (Type 3). Redox Biol 2:749–754 Liao L, Park SK, Xu T, Vanderklish P, Yates JR 3rd (2008) Quantitative proteomic analysis of primary neurons reveals diverse changes in synaptic protein content in fmr1 knockout mice. Proc Natl Acad Sci USA 105:15281–15286 Lin MT, Beal MF (2006) Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature 443:787–795 Loesch DZ, Annesley SJ, Trost N, Bui MQ, Lay ST, Storey E, De Piazza SW, Sanislav O, Francione LM, Hammersley EM et al (2017) Novel blood biomarkers are associated with white matter lesions in fragile X-associated tremor/ataxia syndrome. Neurodegener Dis 17:22–30 Matic K, Eninger T, Bardoni B, Davidovic L, Macek B (2014) Quantitative phosphoproteomics of murine Fmr1-KO cell lines provides new insights into FMRP-dependent signal transduction mechanisms. J Proteome Res 13:4388–4397 Matilainen O, Quirós PM, Auwerx J (2017) Mitochondria and epigenetics-crosstalk in homeostasis and stress. Trends Cell Biol 27:453–463 Maulucci G, Labate V, Mele M, Panieri E, Arcovito G, Galeotti T, Østergaard H, Winther JR, De Spirito M, Pani G (2008) High-resolution imaging of redox signaling in live cells through an oxidation-sensitive yellow fluorescent protein. Sci Signal 1:pl3 Misgeld T, Schwarz TL (2017) Mitostasis in neurons: maintaining mitochondria in an extended cellular architecture. Neuron 96:651–666 Monzo K, Dowd SR, Minden JS, Sisson JC (2010) Proteomic analysis reveals CCT is a target of fragile X mental retardation protein regulation in Drosophila. Dev Biol 340:408–418 Napoli E, Ross-Inta C, Wong S, Omanska-Klusek A, Barrow C, Iwahashi C, Garcia-Arocena D, Sakaguchi D, Berry-Kravis E, Hagerman R et al (2011) Altered zinc transport disrupts mitochondrial protein processing/import in fragile X-associated tremor/ataxia syndrome. Hum Mol Genet 20:3079–3092 Napoli E, Song G, Wong S, Hagerman R, Giulivi C (2016) Altered bioenergetics in primary dermal fibroblasts from adult carriers of the FMR1 premutation before the onset of the neurodegenerative disease fragile X-associated tremor/ataxia syndrome. Cerebellum 15:552–564 Pasciuto E, Bagni C (2014) SnapShot: FMRP mRNA targets and diseases. Cell 158:1446–1446 Pietrobono R, Tabolacci E, Zalfa F, Zito I, Terracciano A, Moscato U, Bagni C, Oostra BA, Chiurazzi P, Neri G (2005) Molecular dissection of the events leading to inactivation of the FMR1 gene. Hum Mol Genet 14:267–277 Primerano B, Tassone F, Hagerman RJ, Hagerman P, Amaldi F, Bagni C (2002) Reduced FMR1 mRNA translation efficiency in fragile X patients with premutations. RNA 8:1482–1488 Reid MA, Dai Z, Locasale JW (2017) The impact of cellular metabolism on chromatin dynamics and epigenetics. Nat Cell Biol 19:1298–1306 Rizzo G, Pizza F, Scaglione C, Tonon C, Lodi R, Barbiroli B, Ambrosetto P, Martinelli P (2006) A case of fragile X premutation tremor/ataxia syndrome with evidence of mitochondrial dysfunction. Mov Disord 21:1541–1542 Ross-Inta C, Omanska-Klusek A, Wong S, Barrow C, Garcia-Arocena D, Iwahashi C, Berry-Kravis E, Hagerman RJ, Hagerman PJ, Giulivi C (2010) Evidence of mitochondrial dysfunction in fragile X-associated tremor/ataxia syndrome. Biochem J 429:545–552 Rueden CT, Schindelin J, Hiner MC, DeZonia BE, Walter AE, Arena ET, Eliceiri KW (2017) Image J2: ImageJ for the next generation of scientific image data. BMC Bioinform 18:529 Sellier C, Freyermuth F, Tabet R, Tran T, He F, Ruffenach F, Alunni V, Moine H, Thibault C, Page A et al (2013) Sequestration of DROSHA and DGCR8 by expanded CGG RNA repeats alters microRNA processing in fragile X-associated tremor/ataxia syndrome. Cell Rep 3:869–880 Shevchenko A, Tomas H, Havlis J, Olsen JV, Mann M (2006) In-gel digestion for mass spectrometric characterization of proteins and proteomes. Nat Protoc 1:2856–2860 Smeets HJ, Smits AP, Verheij CE, Theelen JP, Willemsen R, van de Burgt I, Hoogeveen AT, Oosterwijk JC, Oostra BA (1995) Normal phenotype in two brothers with a full FMR1 mutation. Hum Mol Genet 4:2103–2108 Song G, Napoli E, Wong S, Hagerman R, Liu S, Tassone F, Giulivi C (2016) Altered redox mitochondrial biology in the neurodegenerative disorder fragile X-tremor/ataxia syndrome: use of antioxidants in precision medicine. Mol Med 22:548–559. https://doi.org/10.2119/molmed.2016.00122 Tabolacci E, Moscato U, Zalfa F, Bagni C, Chiurazzi P, Neri G (2008) Epigenetic analysis reveals a euchromatic configuration in the FMR1 unmethylated full mutations. Eur J Hum Genet 16:1487–1498 Tassone F, Hagerman RJ, Taylor AK, Gane LW, Godfrey TE, Hagerman PJ (2000) Elevated levels of FMR1 mRNA in carrier males: a new mechanism of involvement in the fragile-X syndrome. Am J Hum Genet 66:6–15 Todd PK, Oh SY, Krans A, Pandey UB, Di Prospero NA, Min KT, Taylor JP, Paulson HL (2010) Histone deacetylases suppress CGG repeat-induced neurodegeneration via transcriptional silencing in models of fragile X tremor ataxia syndrome. PLoS Genet 6:e1001240 Todd PK, Oh SY, Krans A, He F, Sellier C, Frazer M, Renoux AJ, Chen KC, Scaglione KM, Basrur V et al (2013) CGG repeat-associated translation mediates neurodegeneration in fragile X tremor ataxia syndrome. Neuron 78:440–455 Usdin K, Kumari D (2015) Repeat-mediated epigenetic dysregulation of the FMR1 gene in the fragile X-related disorders. Front Genet 6:192 Valente S, Mellini P, Spallotta F, Carafa V, Nebbioso A, Polletta L, Carnevale I, Saladini S, Trisciuoglio D, Gabellini C et al (2007) 1,4-Dihydropyridines active on the SIRT1/AMPK pathway ameliorate skin repair and mitochondrial function and exhibit inhibition of proliferation in cancer cells. J Med Chem 59:1471–1491 Xu B, Zhang Y, Zhan S, Wang X, Zhang H, Meng X, Ge W (2018) Proteomic profiling of brain and testis reveals the diverse changes in ribosomal proteins in fmr1 knockout mice. Neuroscience 371:469–483 Zhang YQ, Matthies HJ, Mancuso J, Andrews HK, Woodruff E 3rd, Friedman D, Broadie K (2004) The Drosophila fragile X-related gene regulates axoneme differentiation during spermatogenesis. Dev Biol 270:290–307 Zhang YQ, Friedman DB, Wang Z, Woodruff E 3rd, Pan L, O'Donnell J, Broadie K (2005) Protein expression profiling of the drosophila fragile X mutant brain reveals up-regulation of monoamine synthesis. Mol Cell Proteomics 4:278–290